AU2013360889C1 - Vaccine composition for naive subjects - Google Patents

Vaccine composition for naive subjects Download PDF

Info

Publication number
AU2013360889C1
AU2013360889C1 AU2013360889A AU2013360889A AU2013360889C1 AU 2013360889 C1 AU2013360889 C1 AU 2013360889C1 AU 2013360889 A AU2013360889 A AU 2013360889A AU 2013360889 A AU2013360889 A AU 2013360889A AU 2013360889 C1 AU2013360889 C1 AU 2013360889C1
Authority
AU
Australia
Prior art keywords
vaccine
virus
influenza
group
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013360889A
Other languages
English (en)
Other versions
AU2013360889B2 (en
AU2013360889A1 (en
Inventor
Hans Arwidsson
Anna-Karin Maltais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EUROCINE VACCINES AB
Original Assignee
EUROCINE VACCINES AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EUROCINE VACCINES AB filed Critical EUROCINE VACCINES AB
Publication of AU2013360889A1 publication Critical patent/AU2013360889A1/en
Publication of AU2013360889B2 publication Critical patent/AU2013360889B2/en
Application granted granted Critical
Publication of AU2013360889C1 publication Critical patent/AU2013360889C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013360889A 2012-12-17 2013-12-17 Vaccine composition for naive subjects Ceased AU2013360889C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1 2012-12-17
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Publications (3)

Publication Number Publication Date
AU2013360889A1 AU2013360889A1 (en) 2015-07-02
AU2013360889B2 AU2013360889B2 (en) 2016-12-01
AU2013360889C1 true AU2013360889C1 (en) 2017-06-08

Family

ID=47358019

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013360889A Ceased AU2013360889C1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects
AU2013360890A Ceased AU2013360890B2 (en) 2012-12-17 2013-12-17 Vaccine composition for use in immuno-compromised populations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2013360890A Ceased AU2013360890B2 (en) 2012-12-17 2013-12-17 Vaccine composition for use in immuno-compromised populations

Country Status (12)

Country Link
US (2) US20150306204A1 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502997A (enExample)
KR (3) KR20150132092A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014174A2 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007688A (enExample)
RU (2) RU2661408C2 (enExample)
WO (2) WO2014095943A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2621524A1 (en) * 2010-09-30 2013-08-07 Eurocine Vaccines AB Improved vaccine compositions
AU2015323334B2 (en) * 2014-09-26 2021-02-25 Seqirus UK Limited Vaccination of immunocompromised subjects
HUE060456T2 (hu) * 2014-09-26 2023-03-28 Seqirus Uk Ltd Immunkompromittált alanyok oltása
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
EP4135519B1 (en) * 2020-04-16 2024-09-25 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
PL4135520T3 (pl) * 2020-04-16 2025-02-17 Bayer Aktiengesellschaft Kombinacje związków aktywnych i kompozycje grzybobójcze je zawierające
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
US20250177515A1 (en) * 2022-01-10 2025-06-05 The Children's Medical Center Corporation Methods and compositions relating to immunization of immune distinct patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US20030072764A1 (en) 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
WO2004042000A2 (en) 2002-05-17 2004-05-21 Human Genome Sciences, Inc. 157 human secreted proteins
WO2004047862A1 (en) 2002-11-26 2004-06-10 Eurocine Ab Novel amine-based adjuvant
CN103446582A (zh) 2003-08-11 2013-12-18 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
CN101213199B (zh) 2005-06-30 2013-12-18 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
CN101257919B (zh) 2005-08-05 2012-08-29 国立大学法人德岛大学 可以由选择性产生IgA抗体向产生IgA和IgG两种抗体转换的抗原药物载体和使用该载体的经鼻·粘膜疫苗
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
WO2009071633A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
AU2009293595A1 (en) 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042003A1 (en) * 2010-09-30 2012-04-05 Eurocine Vaccines Ab Improved vaccine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETERSSON P. et al, The Eurocine® L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination, Vaccine, 28 (2010) 6491-6497 *

Also Published As

Publication number Publication date
CN104884085A (zh) 2015-09-02
BR112015014243A2 (pt) 2017-07-11
RU2661408C2 (ru) 2018-07-16
BR112015014243A8 (pt) 2019-10-08
JP2016502997A (ja) 2016-02-01
AU2013360890A1 (en) 2015-07-02
KR20210007042A (ko) 2021-01-19
JP2019112448A (ja) 2019-07-11
EP3431101A1 (en) 2019-01-23
AU2013360889B2 (en) 2016-12-01
HK1212611A1 (zh) 2016-06-17
US20150306205A1 (en) 2015-10-29
MX2015007688A (es) 2015-09-07
KR20150132092A (ko) 2015-11-25
RU2661407C2 (ru) 2018-07-16
CN112826929A (zh) 2021-05-25
WO2014095944A1 (en) 2014-06-26
AU2013360889A1 (en) 2015-07-02
WO2014095943A1 (en) 2014-06-26
CA2895023A1 (en) 2014-06-26
RU2015129077A (ru) 2017-01-23
JP2016502996A (ja) 2016-02-01
AU2013360890B2 (en) 2017-04-13
BR112015014174A2 (pt) 2017-07-11
HK1213492A1 (zh) 2016-07-08
EP2931308B1 (en) 2018-10-10
EP2931307A1 (en) 2015-10-21
EP2742952A1 (en) 2014-06-18
CN104870010A (zh) 2015-08-26
MX2015007753A (es) 2016-01-08
KR20150132093A (ko) 2015-11-25
EP2931307B1 (en) 2018-09-12
EP2931308A1 (en) 2015-10-21
RU2015129028A (ru) 2017-01-23
US11065325B2 (en) 2021-07-20
CA2895028A1 (en) 2014-06-26
US20150306204A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
AU2013360889C1 (en) Vaccine composition for naive subjects
US11564984B2 (en) Influenza vaccine
US20080014217A1 (en) Influenza vaccine
BRPI0621886A2 (pt) composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antìgeno de vìrus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antìgeno de vìrus da influenza pandêmica ou preparação antigênica do antìgeno de hemaglutinina do vìrus da influenza e de um adjuvante em emulsão óleo-em-água e de um antìgeno ou preparação antigênica de uma primeira cepa de influenza
JP5918870B2 (ja) インフルエンザに対する改善されたワクチン接種
JP2009209086A (ja) 粘膜投与型ワクチン
US20230201329A1 (en) Influenza vaccine
US20240398930A1 (en) A vaccine for coronavirus and influenza virus, and method for preparation thereof
CA2583555C (en) Influenza vaccine

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 FEB 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 FEB 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired